BCL2L1 and cancer: Targeting of the anti-apoptotic protein BCL-XL together with anti-mitotic agents has been proposed as an efficient therapeutic strategy for different human cancers, including triple-negative breast cancer (TNBC), a particular aggressive subtype of breast cancer 1.